Private Capital Advisors’s Agios Pharmaceuticals AGIO Stock Holding History

Private Capital Advisors’s Portfolio AGIO Stock Details AGIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-4,800	Closed	-$533K	–	113
2015 Q2	$533K	Buy	+4,800	New	+$517K	0.17%	100

Other funds holding AGIO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

FV2GP

Flagship Ventures 2007 General Partner Cambridge, Massachusetts $107M AUM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Private Capital Advisors's AGIO Position: Q3 2015 in Review

Private Capital Advisors sold out of Agios Pharmaceuticals (AGIO) in Q3 2015, closing a stake of 4,800 shares — an estimated $533K sold.

Private Capital Advisors first reported a position in AGIO in Q2 2015 and held it in 1 quarter. The position peaked at $533K in Q2 2015. 150 funds tracked by Wall St. Rank hold AGIO as of Q3 2015.

Private Capital Advisors reported no remaining Agios Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
Private Capital Advisors sold 4,800 Agios Pharmaceuticals shares in Q3 2015, an estimated $533K.
Private Capital Advisors first reported a position in Agios Pharmaceuticals in Q2 2015 and held it in 1 quarter.
Private Capital Advisors's Agios Pharmaceuticals position peaked at $533K in Q2 2015.
150 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q3 2015.

Based on Private Capital Advisors's 13F filing for Q3 2015, filed 6 Nov 2015.